Related Experiment Videos
[Primary plasma cell leukemia--a comprehensive analysis of 44 cases]
1Zhongshan Hospital, Shanghai Medical College.
Summary
Primary plasma cell leukemia (PPCL) presents differently from multiple myeloma (MM), with younger patients, abrupt onset, and distinct clinical features. Early diagnosis and novel treatments like bone marrow transplantation may improve outcomes for this acute leukemia subtype.
Area of Science:
- Hematology
- Oncology
Background:
- Primary plasma cell leukemia (PPCL) is a rare and aggressive hematologic malignancy.
- Distinguishing PPCL from multiple myeloma (MM) is crucial for appropriate treatment and prognosis.
Purpose of the Study:
- To compare the clinical features of primary plasma cell leukemia (PPCL) with multiple myeloma (MM).
- To establish PPCL as a distinct entity from MM based on clinical, cytologic, and cytogenetic differences.
Main Methods:
- Retrospective analysis of four PPCL cases and comparison with 57 MM cases.
- Review of 40 additional reported PPCL cases in China.
- Analysis of clinical presentation, laboratory findings, bone marrow morphology, and radiographic data.
Main Results:
- PPCL patients were younger (mean age 45.2 years) with abrupt onset (≤2 months diagnosis in 77%).
- PPCL exhibited frequent hepatosplenomegaly (81.8% liver, 59.1% spleen), sternal tenderness (61.4%), marked anemia, and abnormal white blood cell counts.
- Bone marrow showed increased plasma cells (mean 69%) with immature forms; bone destruction was rare (31.7%).
- Chemotherapy response was poor (18% total response) with a median survival of 2 months.
- Significant differences in clinical, cytologic, cytogenetic, and ultrastructural features distinguished PPCL from MM.
Conclusions:
- Primary plasma cell leukemia is a distinct acute leukemia subtype, separate from multiple myeloma.
- High-dose alkylating agents combined with autologous bone marrow transplantation may offer improved prognosis for PPCL patients.